Oncology Hematology Care, Inc. - Blue Ash
Cincinnati, OH
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
Teclistamab
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials